




Searching News Database: methotrexate
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
HSMN NewsFeed - 12 Jun 2019
CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals, Name Change To Azurity Pharmaceuticals
CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals, Name Change To Azurity Pharmaceuticals
HSMN NewsFeed - 29 Jan 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
HSMN NewsFeed - 16 Nov 2016
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
HSMN NewsFeed - 17 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
HSMN NewsFeed - 18 Nov 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
HSMN NewsFeed - 15 Sep 2014
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
HSMN NewsFeed - 19 Nov 2013
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 16 Oct 2013
Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker as President and CEO
Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker as President and CEO
HSMN NewsFeed - 13 Nov 2012
Antares Pharma Announces Positive Results from Final MTX Medi-Jet(TM) Clinical Study
Antares Pharma Announces Positive Results from Final MTX Medi-Jet(TM) Clinical Study
HSMN NewsFeed - 29 Oct 2012
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
HSMN NewsFeed - 4 Aug 2011
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
HSMN NewsFeed - 18 Sep 2008
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
HSMN NewsFeed - 30 Jun 2008
William D. Schwieterman, M.D. Joins Chelsea Therapeutics' Board of Directors
William D. Schwieterman, M.D. Joins Chelsea Therapeutics' Board of Directors
HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 20 Mar 2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 11 Dec 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 20 Nov 2007
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 12 Nov 2007
FDA Accepts Chelsea Therapeutics' Investigational New Drug Application for Droxidopa
FDA Accepts Chelsea Therapeutics' Investigational New Drug Application for Droxidopa
HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
HSMN NewsFeed - 14 Aug 2007
European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations for Droxidopa
European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations for Droxidopa
HSMN NewsFeed - 25 Jul 2007
Fourth ACTEMRA(TM) (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
Fourth ACTEMRA(TM) (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
HSMN NewsFeed - 14 Jun 2007
CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
HSMN NewsFeed - 19 Apr 2007
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
HSMN NewsFeed - 6 Nov 2006
Mayne Pharma (USA) Inc. Announces the Launch of Epirubicin Hydrochloride for Injection
Mayne Pharma (USA) Inc. Announces the Launch of Epirubicin Hydrochloride for Injection
HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
HSMN NewsFeed - 3 Oct 2006
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Additional items found! 188

Members Archive contains
188 additional stories matching:
methotrexate
(Password required)
methotrexate
(Password required)